ANSWER: B

Rationale:

Pharmacodynamics (PD) encompasses what the drug does to the body — its mechanisms of action at receptors, enzymes, ion channels, and transporters, and the resulting physiological or pathological changes. Pharmacokinetics (PK), by contrast, describes what the body does to the drug — absorption, distribution, metabolism, and excretion (ADME). Option A defines pharmacokinetics. Option C describes pharmacogenomics. Option D pertains to pharmaceutical science and biopharmaceutics. Option E describes pharmacovigilance and adverse drug reaction classification, a distinct subdiscipline.

ANSWER: C

Rationale:

Paul Ehrlich developed the concept of selective toxicity — the idea that a chemical compound could be designed to target a pathogen or abnormal cell while sparing normal host tissue. This concept underpinned his development of arsphenamine (Salvarsan, compound 606), the first modern synthetic antimicrobial agent, used against Treponema pallidum. Option A refers to A.J. Clark's occupancy theory. Option B describes Raymond Ahlquist's landmark 1948 work classifying adrenoceptors. Option D refers to work formalized by Schild and colleagues. Option E relates to the work of Langley and later Dale on autonomic neurotransmission.

ANSWER: C

Rationale:

Paul Ehrlich developed the concept of selective toxicity — the idea that a chemical compound could be designed to target a pathogen or abnormal cell while sparing normal host tissue. This concept underpinned his development of arsphenamine (Salvarsan, compound 606), the first modern synthetic antimicrobial agent, used against Treponema pallidum. Option A refers to A.J. Clark's occupancy theory. Option B describes Raymond Ahlquist's landmark 1948 work classifying adrenoceptors. Option D refers to work formalized by Schild and colleagues. Option E relates to the work of Langley and later Dale on autonomic neurotransmission.

ANSWER: C

Rationale:

INN stems encode pharmacological class and are a powerful clinical tool for rapid drug class identification. The stem "-sartan" designates angiotensin II receptor blockers (ARBs), exemplified by losartan, valsartan, irbesartan, candesartan, and olmesartan. Option A is incorrect — ACE inhibitors carry the stem "-pril" (e.g., lisinopril, enalapril, ramipril). Option B is incorrect — beta-blockers carry the stem "-olol" (e.g., metoprolol, atenolol, propranolol). Option D is incorrect — dihydropyridine calcium channel blockers carry the stem "-dipine" (e.g., amlodipine, nifedipine). Option E is incorrect — statins carry the stem "-statin" (e.g., atorvastatin, rosuvastatin).

ANSWER: D

Rationale:

Insulin glargine is a recombinant DNA-derived biologic insulin analog. It is produced in Escherichia coli or Saccharomyces cerevisiae expression systems and incorporates two specific structural modifications — substitution of asparagine with glycine at position A21 and addition of two arginine residues at the C-terminus of the B chain — that shift its isoelectric point to pH 7, causing microprecipitate formation at physiological pH and producing a prolonged, peakless absorption profile. Option A is incorrect — animal-source insulins extracted directly from pancreatic tissue (bovine or porcine) are natural products; glargine is not. Option B is incorrect — insulin is a peptide, not a small molecule, and glargine is recombinant, not synthesized chemically. Option C is incorrect — semisynthetic refers to chemical modification of a naturally extracted precursor; glargine is produced by recombinant expression. Option E describes exenatide, derived from exendin-4 found in Gila monster saliva, which is a glucagon-like peptide-1 (GLP-1) receptor agonist, not an insulin.

ANSWER: B

Rationale:

The ATC classification system organizes drugs into five hierarchical levels. The first level is the anatomical main group designated by a single letter. C designates the cardiovascular system. For reference, C10AA05 is atorvastatin: C = cardiovascular system, C10 = lipid-modifying agents, C10A = lipid-modifying agents (plain), C10AA = HMG-CoA reductase inhibitors (statins), C10AA05 = atorvastatin. Option A is incorrect — the nervous system is designated N. Option C is incorrect — alimentary tract and metabolism is designated A. Option D is incorrect — systemic anti-infectives are designated J. Option E is incorrect — the musculoskeletal system is designated M.

ANSWER: B

Rationale:

Raymond Ahlquist, in his 1948 paper published in the American Journal of Physiology, demonstrated that the rank order of potency of six sympathomimetic amines differed systematically across tissue preparations. Two consistent and irreconcilable rank orders emerged, which he used to postulate the existence of two distinct adrenoceptor types — alpha and beta. This conceptual framework directly enabled James Black's development of propranolol (the first beta-blocker) and transformed cardiovascular pharmacology. Option A describes the work of Langley and later Dale distinguishing nicotinic and muscarinic cholinergic receptors. Option C describes Clark's occupancy theory. Option D describes the Schild analysis of competitive antagonism. Option E describes structure-activity relationship (SAR) analysis and pharmacophore modeling.

ANSWER: C

Rationale:

Rational prescribing, as defined by the WHO's "Guide to Good Prescribing," is a structured six-step process: (1) define the patient's problem, (2) specify the therapeutic objective, (3) verify whether your personal formulary drug is suitable for this patient, (4) start treatment, (5) provide information, instruction, and warning, and (6) monitor and stop if necessary. The core principle is individualized, evidence-based selection of therapy optimized for a specific patient. Option A incorrectly reduces rational prescribing to cost minimization alone. Option B is incorrect — novelty is not a criterion for rational prescribing; newer is not inherently better. Option D is incorrect — the Essential Medicines List is a resource tool, not an absolute prescribing constraint in all settings. Option E is incorrect — guideline adherence is one input, but rational prescribing explicitly requires individualization for comorbidities, concurrent medications, patient preferences, and contraindications.